Yervoy Extends Survival of Terminal Melanoma Patients, Same Might Hold True for Other Immunotherapies: Prof.

Hiroyoshi Nishikawa, Associate Professor, Immunology Frontier Research Center of Osaka University Some 20-30% of patients with terminal malignant melanoma lived for 10 years after they took Bristol-Myers Squibb’s cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor Yervoy (ipilimumab), offering hope to patients...read more